We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+16.35%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$239M
AUM Growth
-$103M
(-30%)
Cap. Flow
-$106M
Cap. Flow
% of AUM
-44.2%
Top 10 Holdings %
Top 10 Hldgs %
35.32%
Holding
114
New
39
Increased
6
Reduced
19
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$3.8M |
| 2 |
HCA Healthcare
HCA
|
+$3.62M |
| 3 |
HOLX
Hologic
HOLX
|
+$3.59M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$3.47M |
| 5 |
Medtronic
MDT
|
+$3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$9.9M |
| 2 |
Centene
CNC
|
+$7.74M |
| 3 |
AGN
Allergan plc
AGN
|
+$7.17M |
| 4 |
DexCom
DXCM
|
+$6.24M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$6.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.43% |
| 2 | Industrials | 2.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Axogen
AXGN
$2.5B
| $3.4M | 1.42% |
120,000
-109,278
| -48% | -$2.58M |
|
|
VRAY
27
DELISTED
ViewRay, Inc.
VRAY
| $3.35M | 1.4% |
362,000
-245,040
| -40% | -$1.96M |
|
|
28
PUT
DexCom
DXCM
$32B
| $3.27M | 1.37% |
+227,600
| New | +$2.96M |
|
29
CALL
CVS Health
CVS
$122B
| $3.26M | 1.37% |
+45,000
| New | +$3.27M |
|
|
XENT
30
DELISTED
Intersect ENT, Inc
XENT
| $3.24M | 1.36% |
100,000
-100,000
| -50% | -$3M |
|
31
CALL
Globus Medical
GMED
$11.2B
| $3.23M | 1.35% |
+78,600
| New | +$2.75M |
|
|
EVHC
32
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $3.11M | 1.3% |
90,000
-33,192
| -27% | -$1.16M |
|
33
United Therapeutics
UTHR
$23.1B
| $3.09M | 1.29% |
+20,909
| New | +$2.66M |
|
34
PUT
Bristol-Myers Squibb
BMY
$132B
| $3.06M | 1.28% |
+50,000
| New | +$3.13M |
|
|
35
Medtronic
MDT
$112B
| $3.03M | 1.27% |
+37,500
| New | +$3M |
|
36
CALL
Intuitive Surgical
ISRG
$134B
| $2.92M | 1.22% |
24,000
-12,000
| -33% | -$1.5M |
|
|
VAR
37
PUT
DELISTED
Varian Medical Systems, Inc.
VAR
| $2.78M | 1.16% |
+25,000
| New | +$2.69M |
|
38
Insulet
PODD
$9.79B
| $2.76M | 1.15% |
+40,000
| New | +$2.63M |
|
39
Medpace
MEDP
$16.5B
| $2.54M | 1.06% |
+70,000
| New | +$2.45M |
|
40
Exelixis
EXEL
$13.4B
| $2.43M | 1.02% |
+80,000
| New | +$2.13M |
|
|
ALXN
41
DELISTED
Alexion Pharmaceuticals
ALXN
| $2.38M | 1% |
19,900
-4,000
| -17% | -$487K |
|
42
Rigel Pharmaceuticals
RIGL
$750M
| $2.35M | 0.98% |
+60,456
| New | +$2.3M |
|
|
OTIC
43
DELISTED
Otonomy, Inc.
OTIC
| $2.25M | 0.94% |
+404,742
| New | +$1.76M |
|
|
ESRX
44
DELISTED
Express Scripts Holding Company
ESRX
| $2.24M | 0.94% |
30,000
-70,000
| -70% | -$4.48M |
|
|
45
CALL
HCA Healthcare
HCA
$89.5B
| $2.2M | 0.92% |
+25,000
| New | +$2.01M |
|
46
CALL
Incyte
INCY
$24.4B
| $1.89M | 0.79% |
+20,000
| New | +$2.09M |
|
47
Regeneron Pharmaceuticals
REGN
$80.8B
| $1.88M | 0.79% |
+5,000
| New | +$2.02M |
|
|
CDTX
48
DELISTED
Cidara Therapeutics
CDTX
| $1.87M | 0.78% |
+13,750
| New | +$2.09M |
|
49
Viking Therapeutics
VKTX
$4B
| $1.76M | 0.74% |
+433,900
| New | +$1.26M |
|
|
DCPH
50
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $1.54M | 0.65% |
68,154
-1,846
| -3% | -$36.1K |
|
Similar funds
BCA
ONGA
RC
DOFI
SR
SCI
LPC
GBCP
Pura Vida Investments's Q4 2017 Portfolio in Review
As of Q4 2017, Pura Vida Investments held 114 positions worth $239M, down 30% from $342M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Pura Vida Investments withdrew a net $106M in Q4 2017, closing 45 positions and reducing 19 holdings. Its most notable exit was Merck, an estimated $9.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 50% a quarter earlier, followed by Industrials.
Against the trend, Pura Vida Investments opened a new position in BioMarin Pharmaceuticals worth $3.9M.
- Pura Vida Investments's largest Q4 2017 buy was BioMarin Pharmaceuticals: 43,700 shares worth $3.9M.
- Pura Vida Investments added most to Zogenix, Inc. in Q4 2017, an estimated $3.47M increase.
- Pura Vida Investments's biggest Q4 2017 reduction was LivaNova, cutting an estimated $5.1M.
- Pura Vida Investments fully exited Merck in Q4 2017, selling an estimated $9.9M.
- Pura Vida Investments's ten largest holdings make up 35% of its $239M portfolio in Q4 2017.
- Pura Vida Investments opened 39 new positions and closed 45 in Q4 2017.
- Pura Vida Investments's portfolio value fell 30% quarter-over-quarter to $239M.
Based on Pura Vida Investments's 13F filing for Q4 2017, filed 14 Feb 2018.